MX381092B - Inhibidores de fucosidasa. - Google Patents

Inhibidores de fucosidasa.

Info

Publication number
MX381092B
MX381092B MX2018001315A MX2018001315A MX381092B MX 381092 B MX381092 B MX 381092B MX 2018001315 A MX2018001315 A MX 2018001315A MX 2018001315 A MX2018001315 A MX 2018001315A MX 381092 B MX381092 B MX 381092B
Authority
MX
Mexico
Prior art keywords
inhibitors
tumors
fucosidase inhibitors
fucosidase
liver
Prior art date
Application number
MX2018001315A
Other languages
English (en)
Other versions
MX2018001315A (es
Inventor
Amanda Anne Ko
Sara Louise Isbell
Todd C Zankel
Original Assignee
Horizon Orphan Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Orphan Llc filed Critical Horizon Orphan Llc
Publication of MX2018001315A publication Critical patent/MX2018001315A/es
Publication of MX381092B publication Critical patent/MX381092B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere, en general, a compuestos que son de utilidad como inhibidores de las enzimas fucosidasa y a métodos y composiciones para el tratamiento de tumores o cánceres, tales como trastornos hepáticos y tumores de hígado (por ejemplo, carcinoma hepatocelular), con un compuesto descrito en la presente.
MX2018001315A 2015-07-30 2016-07-29 Inhibidores de fucosidasa. MX381092B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199194P 2015-07-30 2015-07-30
PCT/US2016/044607 WO2017019925A1 (en) 2015-07-30 2016-07-29 Fucosidase inhibitors

Publications (2)

Publication Number Publication Date
MX2018001315A MX2018001315A (es) 2018-08-15
MX381092B true MX381092B (es) 2025-03-12

Family

ID=56616083

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001315A MX381092B (es) 2015-07-30 2016-07-29 Inhibidores de fucosidasa.

Country Status (15)

Country Link
US (2) US9951013B2 (es)
EP (1) EP3328832B1 (es)
JP (2) JP6981961B2 (es)
KR (1) KR20180030699A (es)
CN (1) CN107848970B (es)
AR (1) AR105540A1 (es)
AU (2) AU2016298324A1 (es)
BR (1) BR112018000961A2 (es)
CA (1) CA2992033A1 (es)
IL (1) IL256662B (es)
MX (1) MX381092B (es)
RU (1) RU2765202C2 (es)
TW (1) TWI777923B (es)
WO (1) WO2017019925A1 (es)
ZA (1) ZA201800638B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CA2739897C (en) 2008-10-07 2017-10-03 Mpex Pharmaceuticals, Inc. Aerosol fluoroquinolone formulations for improved pharmacokinetics
CA2739893C (en) 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
SI2473170T1 (sl) 2009-09-04 2019-10-30 Horizon Orphan Llc Uporaba aerosoliziranega levofloksacina za zdravljenje cistične fibroze
RU2765202C2 (ru) 2015-07-30 2022-01-26 ХОРАЙЗОН ОРФАН ЭлЭлСи Ингибиторы фукозидазы
EP4077371B1 (en) * 2019-12-19 2024-01-10 Merck Patent GmbH Methods and compositions for modulating the glycosylation profile of proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US5096909A (en) 1989-06-27 1992-03-17 Monsanto Company Fucosidase inhibitor
US5100797A (en) 1989-06-27 1992-03-31 Monsanto Company Fucosidase inhibitors
US5153325A (en) 1989-06-27 1992-10-06 Monsanto Company Fucosidase inhibitor
US5017704A (en) 1989-06-27 1991-05-21 Monsanto Company Fucosidase inhibitor
US5240707A (en) 1990-04-12 1993-08-31 Merrell Dow Pharma Alpha-mannosidase and fucosidase inhibitors
DE69527942T2 (de) * 1994-01-26 2003-03-27 Novartis Ag, Basel Modifizierte oligonukleotide
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
WO2010015816A2 (en) * 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
KR101784539B1 (ko) 2010-01-28 2017-10-11 랩터 파마슈티컬스 인코포레이티드 수용체 결합 단백질(ｒａｐ) 펩타이드-푸코시다제 억제제 접합체를 이용한 간 질환의 치료방법
BR112014014808A2 (pt) * 2011-12-22 2018-09-25 Centogene Ip Gmbh combinações de um composto que tem a capacidade de reorganizar uma enzima lisossômica e ambroxol e/ou um derivado de ambroxol, sua utilização, preparação farmacêutica e seu método de preparação
WO2014032184A1 (en) * 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
RU2765202C2 (ru) 2015-07-30 2022-01-26 ХОРАЙЗОН ОРФАН ЭлЭлСи Ингибиторы фукозидазы

Also Published As

Publication number Publication date
IL256662A (en) 2018-02-28
KR20180030699A (ko) 2018-03-23
CN107848970A (zh) 2018-03-27
MX2018001315A (es) 2018-08-15
TW201713620A (zh) 2017-04-16
US20190077756A1 (en) 2019-03-14
CN107848970B (zh) 2021-07-06
WO2017019925A1 (en) 2017-02-02
TWI777923B (zh) 2022-09-21
US10308607B2 (en) 2019-06-04
RU2018107143A3 (es) 2019-12-27
BR112018000961A2 (pt) 2018-09-18
US20170029376A1 (en) 2017-02-02
IL256662B (en) 2021-06-30
AU2020289858A1 (en) 2021-01-28
EP3328832A1 (en) 2018-06-06
US9951013B2 (en) 2018-04-24
AR105540A1 (es) 2017-10-11
JP2018522023A (ja) 2018-08-09
RU2018107143A (ru) 2019-08-29
JP6981961B2 (ja) 2021-12-17
RU2765202C2 (ru) 2022-01-26
CA2992033A1 (en) 2017-02-02
ZA201800638B (en) 2022-08-31
JP2021152078A (ja) 2021-09-30
AU2016298324A1 (en) 2018-01-25
EP3328832B1 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
PH12018500718A1 (en) Compounds useful as modulators of trpm8
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
UY36419A (es) Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
MX2017012699A (es) Compuestos heterociclicos como inhibidores de demetilasa 1 especifica de lisina (lsd1).
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
UY37018A (es) Inhibidores bicíclicos de pad4
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
GT201700035A (es) Compuestos aminopirimidinilo como inhibidores de jak
EA201890857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
PH12015502028A1 (en) Ido inhibitors
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
UY37017A (es) Inhibidores aza-bencimidazol de pad4
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
CR20150483A (es) Composiciones y métodos para el diagnóstico y tratamiento del cáncer hepático
MX381092B (es) Inhibidores de fucosidasa.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
PH12017501879A1 (en) Methods for treating cancer
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
MX2015010728A (es) Metodos y composiciones para el tratamiento de leucemia.
DOP2016000211A (es) Pirazinas moduladoras de gpr6